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Abstract
Background: Neopetrosiamide A (NeoA) is a 28-amino acid tricyclic peptide originally isolated from a marine sponge as a
tumor cell invasion inhibitor whose mechanism of action is unknown.
Methodology/Principal Findings: We show that NeoA reversibly inhibits tumor cell adhesion, disassembles focal adhesions
in pre-attached cells, and decreases the level of b1 integrin subunits on the cell surface. NeoA also induces the formation of
dynamic, membrane-bound protrusions on the surface of treated cells and the release of membrane-bound vesicles into the
culture medium. Proteomic analysis indicates that the vesicles contain EGF and transferrin receptors as well as a number of
proteins involved in adhesion and migration including: b1 integrin and numerous a integrin subunits; actin and actin-
binding proteins such as cofilin, moesin and myosin 1C; and membrane modulating eps15 homology domain (EHD)
proteins. Surface labeling, trafficking inhibition, and real-time imaging experiments all suggest that b1 integrin-containing
vesicles are released directly from NeoA-induced cell surface protrusions rather than from vesicles generated intracellularly.
The biological activity of NeoA is dependent on its disulfide bond pattern and NMR spectroscopy indicates that the peptide
is globular with a continuous ridge of hydrophobic groups flanked by charged amino acid residues that could facilitate a
simultaneous interaction with lipids and proteins in the membrane.
Conclusions/Significance: NeoA is an anti-adhesive peptide that decreases cell surface integrin levels through a novel, yet
to be elucidated, mechanism that involves the release of adhesion molecule-containing vesicles from the cell surface.
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Introduction
The ability of tumor cells to interact dynamically with the
extracellular matrix (ECM) is an important driver of invasion and
metastasis [1]. A number of compounds have been developed
that block the ability of integrins to bind to their cognate ECM
ligands, including peptides based on the Arg-Gly-Asp (RGD)
sequence found within many ECM proteins [2,3] and integrin-
blocking antibodies [4]. Other compounds block intracellular
signaling events controlled by integrins [5] or metalloproteinase-
mediated ECM destruction, an approach that, unfortunately, has
not yet proven clinically effective [6,7,8]. Phenotypic cell-based
screens have led to the identification of structurally diverse
inhibitors of cancer cell invasion [9] and we developed a positive
readout screen of this type that eliminates actutely cytotoxic
compounds [10] to identify the motuporamines [10,11], strongy-
lophorine-26 [12,13], avinosol [14] and the neopetrosiamides
[15].
Herein, we characterize the cellular mode of action of the 28-
amino acid marine sponge-derived peptide neopetrosiamide A
(NeoA) [15]. In addition to inhibiting tumor cell invasion, NeoA
also inhibits tumor cell adhesion to rigid ECM substrata and it
causes pre-attached cells to round up and retract from the
substratum. The latter retraction is associated with dissolution of
focal adhesions and a decrease in cell surface b1 integrins. NeoA
has three intrachain disulphide bridges that contribute to the
generation of its compact ellipsoid shape with an amphipathic
distribution of outwardly directed polar and hydrophobic residues
which suggests that it may interact with membranes. Indeed,
NeoA also triggers the rapid formation of membranous protru-
sions on the cell surface and the release of membrane-bound
vesicles that contain a number of integrin subunits, adhesion-
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10836associated proteins, and growth factor receptors. Importantly,
these effects of NeoA are rapidly induced, within minutes, before
any cytotoxicity can be observed, and they are reversible upon
peptide removal.
Results
Inhibition of cell invasion by NeoA
We initially reported that NeoA inhibited the invasion of
LS174T colon carcinoma cells that move through reconstituted
basement membrane gels in an amoeboid fashion [15]. Here we
show that NeoA also inhibits the mesenchymal (i.e. elongated cell)
invasion of both MDA-MB-231 breast carcinoma (Figure 1) and
HT-1080 fibrosarcoma cells (Figure S1). The inhibition was
quantified in a positive readout assay for live, non-invasive cells
that we developed and validated previously [10]. Specifically, we
found that NeoA inhibited approximately 3–6 times as many
MDA-MB-231 and HT-1080 cells from invading into basement
membrane gels at concentrations of 6.5 to 16 mM compared to
DMSO-treated controls (Figure 1A, Figure S1A). Morphological-
ly, this inhibition was associated with a rounding of a vast majority
of both cell types on top of the gel (Figure 1B, Figure S1B).
Furthermore, when added to tumor cells that were first allowed to
pre-spread and begin migrating on rigid substrata, NeoA induced
an active cellular retraction and rounding that was associated with
the loss of f-actin-containing leading lamellae (Figure 1C, Figure
S1C).
NeoA disrupts focal adhesions and reversibly reduces
tumor cell adhesion
The ability of NeoA to induce the rounding of pre-spread cells
on a rigid glass substratum was associated with a disruption of
focal adhesions. Specifically, NeoA treatment led to a delocaliza-
tion of the focal adhesion scaffolding proteins paxillin and vinculin
as well as a decrease in the phosphorylated form of focal adhesion
kinase from characteristic longitudinal streaks at the cell-
substratum interface in MDA-MB-231 tumor cells (Figure 2A).
These observations suggested to us that NeoA may decrease cell
adhesion, which was confirmed by quantifying the dose-dependent
inhibition of MDA-MB-231 cell attachment to both collagen type
I and fibronectin (Figure 2B). To better assess the kinetics of this
anti-adhesive effect, cells were pre-spread on fibronectin-coated
dishes, treated with 6.5 mM NeoA, and observed live for 90 min
by phase microscopy (Figure 2C). A clear anti-adhesive rounding
response was observable within 25 minutes and it was very striking
after 45 minutes. All of these anti-adhesive effects were also
observed in HT-1080 tumor cells (Figure S2).
MDA-MB-231 tumor cells treated with 6.5 or 13 mMN e o Af o r
45 min did not display an increase in Annexin V staining,
propidium iodide uptake or activated caspase levels (Figures 3A,
3B). Furthermore, the anti-adhesive cell rounding and retraction
caused by 45 minutes of NeoA treatment was fully reversed
4 hours after compound removal (Figure 3C). Similar results
were observed with HT-1080 cells (Figure 3A, and not shown).
Thus, the initial anti-adhesive effects of NeoA were not likely
caused by cytotoxicity, which was expected given that our initial
anti-invasion screen was designed to detect increases in viable,
non-invasive cells after three hours of compound treatment (10,
15). It is important to point out, however, that there was an
increase in apoptosis when cells were treated much longer than
studied in detail here (i.e. for 24 hours see Figure S3).
Thus, longterm NeoA treatment does induce a degree of
cytotoxicity.
NeoA decreases b1 integrin levels
Based on the loss of cellular adhesion caused by NeoA, we
reasoned that the ability of integrins to interact with ECM ligands
could be affected. Indeed, flow cytometric analysis indicated that
NeoA treatment caused a concentration-dependent decrease in the
median peak cell surface levels of b1 integrin subunits, which are
prominent in both MDA-MB-231 and HT-1080 cells (Figure 4A).
This was reflected by a significant decrease in the percentage of
cells with high levels of b1 integrin on their surface. Specifically,
13 mM NeoA caused a decrease from 88% to 21% of MDA-MB-
231 cells showing considerable levels of b1 integrin on the cell
surface (Figure 4B). Immunoblotting of whole cell lysates also
showed that NeoA induced a large decrease in total cellular b1
integrin (Figure 4C). Importantly, NeoA treatment did not affect
the total levels of the focal adhesion scaffolding protein paxillin
(Figure 4C) despite the fact that paxillin did become diffuse and
delocalized after NeoA-mediated focal adhesion disruption (see
Figure 2A above).
Figure 1. NeoA prevents tumor cell elongation and invasion
into Matrigel. (A) MDA-MB-231 cells were treated with NeoA (or 5 mM
dihydromotuporamine C [10] as a positive control, +ve). Live cells that
failed to invade were recovered and quantified through an MTT assay.
Shown are averages of triplicates 6 SD. ** P,0.005, *** P,0.0005
compared to 0 mM as determined by two-tailed Student’s t-test. (B)
MDA-MB-231 cells were plated on the reconstituted basement
membrane substratum Matrigel in the presence of DMSO vehicle alone
or 6.5 mM NeoA and morphology was assessed by live phase contrast
microscopy after 2.5 h. Scale bar, 50 mm. (C) NeoA treatment results in
loss of polarity and decreased actin ruffling. f-actin staining of cells
treated with either DMSO or 3.2 mM NeoA for 90 min. Note that f-actin-
rich leading lamellae (white arrows in DMSO-treated cells) are greatly
reduced in the NeoA-treated cells. Scale bar, 10 mm.
doi:10.1371/journal.pone.0010836.g001
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occurred very rapidly. It was first noticeable within 20–30 minutes
(not shown) and it was clearly evident after 45 minutes of
treatment (Figure 4), a time frame that was not associated with any
increase in cytotoxicity (see Figures 3A, 3B above). Additionally,
like the morphologic response, the loss of b1 integrin subunits from
the cell surface was fully reversible after compound withdrawal
(Figure 4D).
NeoA triggers the release of intact b1 integrin subunits
from the cell surface
To determine if NeoA induced the release of b1 integrin
subunits from the cell surface, we examined the tissue culture
medium after treatment. Indeed, immunoblotting showed that
NeoA caused tumor cells to release large amounts of b1 integrin
into the medium (Figure 5A). The released b1 integrin had an
electrophoretic mobility of approximately 130 kDa, which is the
Figure 2. NeoA inhibits cellular adhesion and causes the disassembly of focal adhesions in MDA-MB-231 cells. (A) Cells treated for 1 h
with DMSO or 6.5 mM NeoA were fluorescently stained for the focal adhesion proteins paxillin, vinculin, and phosphorylated focal adhesion kinase
(pFAK). Note that all proteins were no longer localized at discrete attachment sites (i.e. focal adhesions) in NeoA-treated cells. Scale bar, 10 mm. (B)
Adhesion to fibronectin (FN) and collagen type I (Col I) is significantly decreased in the presence of NeoA. Shown are averages of triplicates 6 SD.
** P,0.005, *** P,0.0005 compared to 0 mM as determined by two-tailed Student’s t-test. (C) Cells pre-attached on fibronectin begin to lose
adherence between 10 to 25 min after the start of treatment with 6.5 mM NeoA. Scale bar, 50 mm.
doi:10.1371/journal.pone.0010836.g002
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Figure 5A). To verify that b1 integrin subunits were being released
in intact form, we demonstrated that the 130 kDa protein was
recognized by antibodies directed against both the extracellular
and the cytosolic domains of the protein (Figure 5A). In
comparison, NeoA treatment caused no discernible release of
paxillin (Figure 5A). The selective release of full-length b1 integrin
subunits, the lack of toxicity within the time frame of the release
(within 45 minutes), and the recovery of cellular b1 integrin levels
after NeoA withdrawal all suggested to us that this release was not
a consequence of cell lysis.
Pre-treatment of tumor cells with a battery of protease inhibitors
had no effect on the magnitude of the release or the molecular
weight of the released b1 integrin subunits after NeoA treatment
(data not shown). Thus, we next considered the possibility that b1
integrins were being released in vesicles. Following a general
procedure for isolation of small vesicles, the medium of DMSO- or
NeoA-treated cells was subjected to sequential centrifugations,
ending in a 120,000 g ultracentrifugation step; samples of the
supernatants and pellets from the various steps in this procedure
were then immunoblotted. b1 integrin was detected only in the
pellets of the samples from NeoA-treated cells but not from the
Figure 3. NeoA is not toxic to cells at concentrations that inhibit invasion. (A) Cell death and apoptosis of MDA-MB-231 and HT-1080 cells
treated with the indicated concentrations of NeoA for 45 min were determined by assessing propidium iodide uptake (y axis) and Annexin V staining
(x axis) by flow cytometry. Cells undergoing apoptosis stain positively for Annexin V-FITC alone and would appear in the lower right quadrant of the
plots. Dead cells are PI-positive and appear in the upper quadrants, either without having undergone apoptosis (upper left quadrant) or after having
undergone apoptosis (upper right quadrant). Note that NeoA did not increase the number of dead cells of either type compared to the negative
DMSO control treatment. (B) Activated caspase levels were measured using a fluorescence-based kit and levels were assessed in MDA-MB-231 cells by
flow cytometry following a 45 min treatment with NeoA at the indicated concentrations. (C) Morphological reversion following the removal of NeoA.
MDA-MB-231 cells on tissue culture plastic spread prior to treatment; round after a 45 min treatment with 13 mM NeoA; and re-spread 4 h after the
removal of NeoA. Scale bar, 50 mm.
doi:10.1371/journal.pone.0010836.g003
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of the medium from NeoA-treated cells with 1% Triton X-100
prior to centrifugation prevented the detection of b1 integrin in the
NeoA-induced pellet (Figure 5B), suggesting it was associating with
membranous vesicles. This was confirmed by imaging the pellet
from the medium of NeoA-treated cells using transmission electron
microscopy (TEM). While no discernible material was generated
from the conditioned medium of DMSO-treated cells (not shown),
the pellets generated from the conditioned medium of NeoA-
treated cells were composed of membrane-bound vesicles with a
mean diameter of 71 nm (644.5 nm, SD, n=177; Figure 5C).
Actin microfilaments (approximately 6 nm cross-sectional diame-
ter) were observable within the vesicles (inset, Figure 5C) and there
was no evidence of cellular organelles or debris amongst the vesicle
population.
Biochemical characterization of the vesicles released by
NeoA treatment
To determine what cellular proteins were present in NeoA-
generated membrane-bound vesicles, we carried out a quantitative
proteomic analysis. Little protein was detected in the pellets
generated from the ultracentrifugation of conditioned medium
from vehicle control (DMSO)-treated cells. In contrast, the NeoA-
induced pellet contained a number of transmembrane proteins
that included endogenous EGFR and the transferrin receptor
(Figure 6A). The b1 integrin subunit and the a2, a3 and a6
integrin subunits were also prominent in the NeoA pellet. In
addition to actin, which was expected based on the TEM, a
number of actin-binding and membrane-modifying proteins that
have been implicated in cell adhesion, cell migration and cell
surface specializations were also present. These included moesin,
cofilin, EphA2, myosin 1C and EHD proteins (Figure 6A).
Representative mass spectra from the proteomic analyses are
shown (Figure 6B).
To verify the proteomic results, conditioned medium was
subjected to sequential centrifugations, ending in a 120,000 g
ultracentrifugation. Samples of the supernatants and pellets from
the various steps in this procedure were then immunoblotted and
b1 integrin, actin, transferrin receptor, and EGFR were all
detected in the conditioned medium from NeoA-treated cells and
in the pellets (i.e. the vesicle-containing fraction) of the samples
from the NeoA-treated, but not from the vehicle control, DMSO-
treated, cells (Figure 6C).
NeoA triggers the formation of membrane projections
and the release of membrane-bound vesicles from the
cell surface
To further understand the release of vesicles from NeoA-treated
cells, we examined the cell surface by scanning and transmission
electron microscopy (SEM and TEM, respectively). SEM
indicated that DMSO/vehicle control-treated MDA-MB-231 cells
plated on serum-coated coverslips were flat and had small,
somewhat sparse, microvilli on their dorsal surface (Figure 7A).
Within 30 minutes, NeoA caused the cells to round up and,
strikingly, it induced the formation of numerous irregularly shaped
protrusions on the cell surface that were often terminally distended
(inset Figure 7A). TEM indicated that these projections were
membrane-limited and contained filamentous actin (arrow, right
panel inset; Figure 7B). TEM also indicated that the plasma
membrane between the NeoA-induced projections was not
damaged or denuded. In addition, there was no observed increase
in subplasmalemmal vesicles or multivesicular bodies which
suggests that NeoA did not substantially increase intracellular
vesicle trafficking.
Figure 4. NeoA reversibly reduces levels of b1 integrin on the cell surface. (A–B) MDA-MB-231 and HT-1080 cells treated in suspension with
NeoA for 45 min were stained with a FITC-labeled antibody for total b1 integrin and surface levels were evaluated by flow cytometry. (A) Graphical
representation of the shift in the median peak values (averaged from duplicates within one experiment 6 SD) of b1 integrin after treatment with the
NeoA. (B) NeoA lowers the percentage of MDA-MB-231 cells expressing b1 integrins on their surface. (C) Immunoblots of whole cell lysates from cells
treated with 0, 6.5, or 13 mM of NeoA for 45 min. A representative blot from three independent experiments was probed for b1 integrin (b1) and
paxillin (Pax). (D) Decrease in b1 integrin is reversible. MDA-MB-231 cells treated for 45 min with 13 mM NeoA were washed and allowed to recover for
the indicated times. Surface levels of b1 integrin were measured by flow cytometry. All data shown are representative from at least three
independent experiments.
doi:10.1371/journal.pone.0010836.g004
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dynamic and release transmembrane protein-containing
vesicles
The EGFR is a prominent transmembrane protein in MDA-MB-
231 cells [16] and was shown to be released in NeoA-induced vesicles
(Figure 6A,C). Therefore, we expr e s s e da nE G F R - Y F Pf u s i o np r o t e i n
in these cells by transient transfection to mark the plasma membrane
and then imaged the cells, live, by spinning disk confocal microscopy.
In untreated cells, membranous EGFR-YFP was distributed
across much of the cell surface with increased accumulations over
the cell body and at areas of membrane ruffling (arrows,
Figure 8A). Overall there were no striking changes in EGFR-
YFP distribution over a 30 minute observation period of the
untreated cells. Additionally, no decrease in fluorescence intensity
was observed, which indicated a lack of photobleaching over the
30 minute observation period.
Cells began to round and displayed numerous EGFR-YFP-rich
projections within 5 minutes of NeoA addition (Figure 8B).
Subsequently, over the ensuing 25 minutes, much of the EGFR-
YFP intensity was lost from the cell surface (Figure 8B). Upon
examination of individual cell surface projections at higher
magnification over a four minute (240 second) period beginning
five minutes after the addition of NeoA, the projections were
observed to be very dynamic and many of them appeared to
directly release small, discrete EGFR-YFP labeled vesicle-like
structures as shown by the arrowheads in Figure 8C.
In an effort to further assess if vesicles are released directly from
NeoA-induced protrusions, we biotinylated cell surface proteins
prior to treatment and compared cell surface protein levels in
cellular lysates and in the vesicular fractions released in the media.
In untreated controls, the majority of surface-labeled proteins were
present in the cell lysate (Figure 8D). In contrast, in the NeoA-
treated condition, the overall abundance of biotinylated proteins
was reduced in the cell lysate despite the fact that total protein
levels were similar between the untreated and NeoA-treated cell
lysates (compare silver stains and the anti-biotin westerns of the
lysate fractions in Figure 8D). In addition, there was a clear and
notable increase in the number of biotinylated protein species in
the medium/vesicular fraction of the NeoA-treated cells. The
biotinylated band patterns of the cell lysates and medium/
vesicular fractions recovered from NeoA-treated cells were similar
but not identical, suggesting that cell surface proteins were not all
released equally.
The activity of NeoA is temperature-sensitive and
dependent on its compact and distinct amphipathic
structure
In an effort to gain further insight into the mechanisms by
which NeoA induces a reduction in b1 integrins and vesicle release
from the cell surface, we attempted to block this decrease by
various means. Cells infected with a specific inhibitor of
endocytosis (a dominant negative K44A dynamin mutant) or
treated with pharmacologic endocytosis inhibitors (phenylarsine
oxide, nystatin, methyl-b-cyclodextrin) still lost considerable b1
integrin after NeoA treatment (Figure 9A) and they continued to
release NeoA-induced vesicles (assessed with a Nicomp particle
sizer; data not shown). Additionally, inhibitors of intracellular
trafficking (bafilomycin A1, brefeldin A), actin disruptors (cyto-
chalasin D, latrunculin A, jasplakinolide), a microtubule disruptor
(nocodazole), and an inhibitor of macropinocytosis (amiloride) all
had little or no effect on NeoA-induced loss of b1 integrin. The
only effective blockade of NeoA-mediated integrin-release oc-
curred when the incubation temperatures were reduced to either
24uCo r1 8 uC (Figure 9A). This suggested to us that NeoA induces
vesicle release via a mechanism requiring plasma membrane
fluidity.
NeoA consists of 28 standard amino acids, except for a
methionine sulfoxide at position 24, and is a tricyclic peptide
with three disulfide bridges [15]. Using NMR-derived distance
and dihedral angle restraints, we have now determined the three-
dimensional structural ensemble of NeoA. The peptide folds into a
compact, oblate ellipsoid shape. A summary of the restraints and
structural statistics for this ensemble is provided (Table S1).
Although it follows hairpin-like arrangements, the backbone of
NeoA does not exhibit any regular secondary structure with the
exception of residues centered around Arg19 and Asp27 that are
aligned in an anti-parallel b-strand fashion. However, tertiary
folding leads to a distinct amphipathic distribution of polar and
hydrophobic residues. Specifically, with the exception of Phe5, all
hydrophobic groups form a contiguous ridge with the side chain of
the atypical, oxidized methionine (Mso24) located between the
aromatic rings of Phe2, Phe5, and Phe23 (Figure 9B). In a similar
fashion, the charged side chains of Arg16, Arg19, Asp11, Asp20,
and Asp27 are localized on either side of this non-polar cluster.
Thus, given its globular, amphipathic structure it is possible that
NeoA can interact simultaneously with lipids and proteins in the
membrane.
Very recently, Vederas and colleagues generated data indicating
that the specific disulphide linkages in NeoA are: Cys3 to Cys26
(bridge position 1–5), Cys7 to Cys18 (bridge position 2–4), and
Figure 5. NeoA causes the release of intact b1 integrin subunits
and membrane-bound vesicles. (A) Immunoblots of 10X concen-
trated conditioned medium from MDA-MB-231 cells treated with 0, 6.5,
or 13 mM of NeoA for 45 min compared to whole cell lysates (L) of
control cells treated with DMSO alone. Blots were probed using two
distinct b1 integrin antibodies, one recognizing the cytosolic region (b1
cyt) and one recognizing the extracellular region (b1 ext) of the protein,
as well as with an antibody for paxillin (Pax). (B) The released b1 integrin
is associated with a detergent-soluble membrane bound vesicle.
Conditioned medium was collected from cells treated with NeoA and
one sample was pre-incubated with 1% Triton X-100 prior to
ultracentrifugation. Pellets were then immunoblotted for b1 integrin.
(C) TEM of vesicles from the 120,000 g pellet from the conditioned
medium of NeoA treated cells. Scale bar, 0.5 mm.
doi:10.1371/journal.pone.0010836.g005
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demonstrating that a synthetic peptide with this bridge connec-
tivity has anti-invasive activity [17]. Initially, however, we reported
that the natural form of NeoA purified from a marine sponge
extract had a slightly different, ‘alternate’ bridge connectivity of 1–
5, 2–3, 4–6 [15]. The residues involved in the alternate bridging
(ie. Cys7, Cys12, Cys18 and Cys28) are all closely juxtaposed in
the NMR-derived structure and modeling indicates that the
alternate connectivity would not affect the globular amphipathic
nature of the peptide’s structure described above (data not shown).
Despite this, a synthetic peptide containing the alternate bridge
connectivity generated by the Vederas group [17] was not anti-
invasive (Figure 9C), nor did it prevent cell adhesion (Figure 9D).
Therefore, the biological activity of NeoA is likely very sensitive to
the subtle structural changes that the alternative disulphide
bridging gives rise to. This suggests that the peptide’s cellular
target(s) may also be structurally specific.
Discussion
A number of structurally diverse agents that target cellular
invasion, including those that inhibit the controlled invasion of
endothelial cells that drives angiogenesis, act predominantly by
altering the cytoskeleton. This includes the compounds fumagillin,
Figure 6. Characterization of released vesicles. (A) List of the most abundant proteins (based on spectra counts) found preferentially in the
NeoA-treated pellets versus DMSO-treated pellets from MDA-MB-231 cells. Ratios of peptides in NeoA vs. DMSO pellets (NeoA/DMSO) from each of
three experimental replicates analyzed are listed. nd, not detected. (B) Representative mass spectra from proteomic analysis of the pellets from NeoA-
treated (black triangles) and DMSO-treated (open triangles) cells. Triangles mark the position expected for the peptide. Spectra of a protein highly
enriched in the pellet of NeoA-treated cells (left) and of a protein present at similar levels in the pellets from both NeoA-treated and DMSO-treated
cells (right) are shown. (C) b1 integrin (b1), actin, transferrin receptor (TfR), and EGF receptor (EGFR) can all be detected in the conditioned medium
from MDA-MB-231 cells treated with 13 mM NeoA and can be pelleted at high centrifugal speeds. On the gel, from DMSO (2) or NeoA (+) treated
conditions: 5 mg of cell lysate; 50 ml of conditioned medium; 1/4 of pellet from 16,500 g spin; 1/4 of pellet from 120,000 g spin; 50 ml of supernatant
from final spin. Note that, since pellets in this experiment were not re-suspended in the same volume as the supernatant they were pelleted from,
comparisons of protein levels on this blot can only be made between the treated and control samples for each pellet or supernatant.
doi:10.1371/journal.pone.0010836.g006
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motuporamines and strongylophoryine-26 which were identified
by our group [11,13]. All of these compounds increase focal
adhesion stability to inhibit productive cell motility [11,13]. In
contrast, NeoA caused attached and spread cells to retract and
round-up as focal adhesions were dismantled. These effects were
not limited to tumor cells. They also occurred when normal
fibroblasts and endothelial cells were treated with NeoA (data not
shown) which suggests that the peptide is generally anti-adhesive.
NeoA induces cells to form membranous protrusions with
cytoplasmic cores that contain filamentous actin. These membra-
nous protrusions are very prominent on the apical, free surface of
the attached tumor cells and they have a morphology that is
distinct from microvilli, which tend to be shorter (1–2 mm) and
more regular in length and diameter. Microvilli also lack adhesion
proteins such as integrins [19,20] which are most often associated
with the basal, attached surface of adherent cells. On the other
hand, filopodial projections often contain integrins but, unlike
NeoA-induced protrusions, filopodia are often attached to the
substratum. NeoA-induced protrusions were long and often
distended terminally or along their length. Live imaging indicated
that these protrusions formed very quickly, within five minutes,
were highly dynamic, and that vesicles were likely released directly
from their distended portions.
The vesicles released by cells treated with NeoA contained b1
integrin subunits, a integrin subunits, actin and several proteins
that have previously been shown to associate with integrins or
actin. In fact, with the exception of EGFR and transferrin
receptors, which were also present in the vesicles, nearly all of the
19 most prominent proteins found in the vesicles play some role in
cell adhesion or motility. The three most prominent integrin a
subunits detected in the NeoA vesicles can all dimerize with b1
integrin to bind ECM components. EHD1 regulates transport of
b1 integrin [21] and EHD4 has been reported to be involved in
binding to ECM [22]. Additionally, these two EH domain-
containing proteins have been shown to interact with each other
[23]. CD98hc and MCT4 associate together with other proteins in
a complex [24] that also associates with b1 integrin [25,26]. 59-
Figure 7. NeoA induces formation of membrane-bound protrusions. (A) SEM of the cell surface reveals an increase in membrane projections
upon treatment with NeoA. MDA-MB-231 cells treated with DMSO (left panels) or 6.5 mM NeoA (right panels) for 30 min. Different cells are shown
from two magnifications. Scale bars, 2 mm. (B) TEM confirms the presence of membrane protrusions at the apical cell surface. Left panel: cells treated
with DMSO. Middle panel: cells treated for 20 min with 6.5 mM NeoA. Right panel is a higher magnification view of inset outlined by the black box in
the middle panel; Actin filaments indicated by arrow. Scale bars in left and middle panels, 1 mm; in right panel, 0.2 mm.
doi:10.1371/journal.pone.0010836.g007
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adhesion of cancer cells [27] and both CD166 and protein tyrosine
kinase 7 are thought to be cell adhesion molecules [28,29]. Actin,
widely known to be involved in cell motility, is present along with
cofilin-1 which binds actin [30], and moesin and myosin 1C which
link actin to the plasma membrane [31,32]. Our quantitative
proteomic analysis also indicated that a number other integrins
subunits, including b4, b5, a5, and av, were also present in the
vesicles, albeit to a lesser degree (data not shown). The release of
these integrin subunits may explain why the peptide is also anti-
adhesive for endothelial cells, given that the latter utilize av- and
b5-containing integrins to facilitate adhesion to the substratum
[33]. However, it is worth noting that the decrease in b1 integrins
induced by the treatment of tumor cells with NeoA also occurred
when those cells were maintained in suspension (Figure 4). Thus,
in future studies it will be important to determine if the peptide has
integrin-independent effects on adhesion or other cellular
functions.
A relatively unbiased RNAi-based screen found that genes
which modulate b1 integrin and regulators of actin dynamics form
two of three major nodes that regulate cell migration [34]. While
NeoA did not induce the vesicular release of adhesion-modulating
proteins with absolute specificity, these two functional categories of
proteins were highly enriched in the vesicles. Additionally, the
proteins released into the vesicles from the cell surface after
biotinylation were different to those that remained on the cell
surface after NeoA treatment (Figure 8D). Thus, there may be
some specificity to the proteins released from cells in the vesicles
that, due to their loss, could selectively impinge on cell adhesion
and migration.
The effects of NeoA on adhesion occurred rapidly, within
minutes, in the absence of any observable cytotoxicity, and these
effects were fully reversible. However, when cells were treated
continuously with NeoA for 24 hours some apoptosis did occur.
The reasons for the latter cytotoxic response are not yet clear. One
possibility is that longterm NeoA treatment, by virtue of its ability
to dismantle focal adhesions and release cells from the substratum,
may induce the anoikic state of apoptosis that often occurs when
adherent cells are maintained in suspension [35]. Determining if
this is, indeed, the case will require a detailed dose and kinetic
response analysis wherein the ability of NeoA to induce apoptosis
in anoikis-sensitive and resistant cell lines maintained either in
adherent or suspension culture are compared. On the other hand,
we reiterate that NeoA was able to initiate a decrease in cell
surface b1 integrin and vesicle release from cells maintained in
suspension. Thus, it is also possible that the cytotoxic effects of
longterm NeoA treatment are caused by, for example, the large
scale loss of surface membrane regardless of the state of cellular
adhesion. If the latter turns out to be the case it could impact
NeoA’s further development as a potential therapeutic agent given
that the development of adhesion-independent anoikic resistance
appears to be a functionally important phenotype that may
contribute to metastatic tumor progression [36].
Transmission electron micrographic analyses of NeoA-treated
cells did not reveal an increase in multivesicular bodies within the
cell cytoplasm near the plasma membrane as would be expected if
vesicle release was exosomal in nature [37]. In addition, blocking
trafficking pathways that are required for exosomal vesicle
production and release from multivesicular bodies did not prevent
NeoA-mediated vesicle release, and our live imaging analyses
indicated that small, EGFR-decorated structures were released
directly from NeoA-induced surface projections. Furthermore, we
found that NeoA treatment led to a decrease in total cell volume
(data not shown), which is expected if the peptide is causing the
direct release of membrane-bound vesicles from the cell surface
rather than exosome-based release of internally stored membrane-
bound vesicles.
There are reports that serum treatment of MDA-MB-231 breast
cancer cells can induce the direct shedding of vesicles from the cell
surface that contain metalloproteinases (MMPs) [38]. However,
there was no evidence of MMPs in our proteomic analysis of
Figure 8. Vesicles are released from the cell membrane of
NeoA-treated cells. (A–C) Live cell images of MDA-MB-231 cells
transiently transfected with EGFR-YFP at several time points throughout
a 30 minute treatment. Shown are representative cells out of at least 20
cells imaged in 3 separate experiments. (A) Untreated cells. Arrows
point to areas of EGFR at membrane ruffles. (B) Cells treated with
6.5 mM NeoA. Scale bar, 10 mm. (C) Higher magnification view of surface
projections from a NeoA-treated cell marked by the white box in panel
B. After an initial 5 min treatment period the projections were observed
for an additional 240 seconds. Arrowheads point to areas where vesicles
appear to be pinching off from the protrusions. Scale bar, 1 mm. (D) Cell
surface proteins were biotinylated prior to treatment with DMSO or
13 mM NeoA for 45 min at 37uC. Following treatment, cell lysates (L)
and medium (M) were collected. Equal proportions (1/5 of total sample
from the same cell numbers) were run on SDS-PAGE. One gel was silver
stained to indicate total protein(s) while one was transferred and
probed with anti-biotin to indicate proteins that were originally on the
cell surface.
doi:10.1371/journal.pone.0010836.g008
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treated MDA-MB-231 cells did not exhibit increased MMP
activity by enzymatic zymography (data not shown). Therefore,
the mode of NeoA action does not appear to mimic that induced
by serum components that cause direct vesicle shedding from
MDA-MB-231 cells. It is important to note, however, that vesicles
directly shed by activated neutrophils do, like NeoA-induced
vesicles, contain integrins [39]. Regardless, NeoA appears to
induce vesicle shedding by an as yet uncharacterized novel
mechanism.
Figure 9. NeoA’s effects are temperature sensitive and structure dependent. (A) Percent b1 integrin levels (compared to untreated vehicle
controls) on the cell surface of NeoA-treated cells under the indicated temperature conditions (i.e. 37uCo r2 4 uC), or in the presence of the following
inhibitors all at 37uC: wild-type dynamin control (wtDyn); dominant negative dynamin (K44A); phenylarsine oxide (PAO); nystatin (nys); methyl-b-
cyclodextrin (mbcd); bafilomycin (Bafil); brefeldin A (BFA); cytochalasin D (CytD); latrunculin A (LatA); jasplakinolide (Jasp); nocodazole (Noc); or
amiloride (Amil). Surface b1 integrin levels were measured by flow cytometry. Results are averages from two independent experiments. * P,0.05
compared to cells treated at 37uC as determined by two-tailed Student’s t-test. (B) Surface representation of NeoA, with hydrophobic residues shown
in magenta, whereas positively- and negatively-charged residues are in blue (Arg) and red (Asp), respectively. Note the large hydrophobic patch
flanked by charged groups. MDA-MB-231 cells were assayed for (C) invasion and (D) adhesion after treatment with the natural NeoA peptide (Natural
product) or a synthetic peptide with an alternate disulfide bond connectivity (Alternate S-S). Shown are averages of triplicates 6 SD.
doi:10.1371/journal.pone.0010836.g009
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recognized as a contributor to paracrine signaling as it can
facilitate the transfer of proteins and lipid between cells across
extracellular spaces [40] in response to a number of different
stimuli including calcium ionophore- and phorbol ester-mediated
signaling [41]. Thus, while it is possible that NeoA co-opts the
signaling pathways initiated by such compounds to rapidly induce
vesicle shedding within minutes, it is important to note that the
only way we could efficiently block NeoA-mediated vesicle
shedding was to cool cells to temperatures of 24uC or lower. This
suggests that NeoA is only active when plasma membranes are
fluid. Interactions with fluid membranes could be facilitated by the
amphipathic nature of NeoA’s globular structure that may permit
simultaneous interactions with lipids and proteins in the
membrane. If such simultaneous interactions do occur they are
likely highly specific because altering the disulfide bonding pattern
of NeoA, which appears to only change its general globular
amphipathic structure slightly, completely abrogates the biological
activity of the peptide.
Database searching did not yield any known proteins or
peptides with sequences or motifs that are similar to NeoA. Like
NeoA, EGF domains contain three internal cysteine bridges and
these domains, which are found in many proteins, can be anti-
adhesive, particularly when they contain an integrin-binding RGD
sequence [42]. However, NeoA does not contain such an RGD
sequence, does not have the same disulfide bridge connectivity as
EGF domains, and it lacks the prominent secondary structure (i.e.
folded b-sheets) normally found in EGF domains [43]. The ‘P’
conotoxin peptides, which have neurotoxic activity and are
produced by predatory snails, also have three internal cysteine
bridges [44] and like NeoA, require proper disulfide connectivity
for bioactivity [45]. However, ‘P’ conotoxins are composed
primarily of hydrophilic and charged amino acid residues [46]
which means that they are not likely to be amphipathic like NeoA.
Despite our best efforts, we have been unable to determine how
NeoA interacts with cells. This has proven very difficult using the
unlabeled natural product compound, presumably because the
interactions are transient and because attempts to label the natural
product extinguished its biological activity. Very recently, Vederas
and colleagues have been able to synthesize an active form of
NeoA [17]. This should greatly facilitate the structural and
functional analysis of NeoA and make it possible to generate
labeled, active forms of the peptide that should help identify its
precise cellular and molecular targets by optical, biochemical and
immunological means.
Materials and Methods
Cell culture and reagents
Human breast carcinoma MDA-MB-231 and human fibrosar-
coma HT-1080 cells were routinely maintained in monolayer
culture in Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 10% fetal bovine serum (FBS; Invitrogen). All cells
were grown at 37uC in a humidified 5% CO2 incubator. Unless
otherwise noted, cells were harvested using a solution of 0.5 g/l of
trypsin and 0.2 g/l of EDTAN4Na (Invitrogen). In cases where it
was important to keep all cell surface proteins intact, a solution of
enzyme-free 0.2 g/l EDTAN4Na and 0.2 g/l glucose in PBS was
used to dissociate the cells. Inhibitors and reagents used: 10 mM
phenylarsine oxide, 25 mM nystatin, 5 mM methyl-b-cyclodextrin,
100 nM bafilomycin A1, 5 mM brefeldin A, 2 mM cytochalasin D,
2 mM latrunculin A, 10 mM nocodazole, and 3 mM amiloride, all
from Sigma. Jasplakinolide was isolated from a marine sponge
extract and used at 0.5 mM. At all concentrations of inhibitors
tested and when treating cells with NeoA, cells were exposed to
0.5% DMSO (v:v). For labeling of cell surface proteins with biotin,
EZ-Link Sulfo-NHS-SS-Biotin (Pierce) was used according to
manufacturer instructions. The labeling reaction was performed at
4uC to inhibit endocytosis and ensure only cell surface proteins
were labeled prior to treatment with NeoA.
Assay for invasion inhibition
Invasion inhibition assays were performed as previously
described and validated [10]. Briefly, tumor cells were plated on
reconstituted basement membrane gels (Matrigel; BD Biosciences).
After 2.5 h, non-invasive cells were recovered from the top surface
of the Matrigel, and the number of viable cells was quantified
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay.
Immunofluorescence staining
Cells were pre-spread on coverslips in serum-containing
medium and maintained for 48 h. Medium containing NeoA or
DMSO was then added to the cells for the specified lengths of time
prior to fixation. Cells were fixed with 3% paraformaldehyde for
15 min at room temperature, permeabilized with 0.3% Triton X-
100 in PBS for 15 min, and blocked with 3% bovine serum
albumin (BSA; Sigma) in PBS for 30 min, followed by incubation
with mouse anti-human vinculin (Sigma) at 1/50, mouse anti-
human paxillin (BD Biosciences) at 1/50, or rabbit anti-FAK
[pY397] (Invitrogen) at 1/100. An Alexa Fluor 568-conjugated
goat anti-mouse secondary antibody (Molecular Probes) was used
at a dilution of 1 in 100 and imaged using an Olympus FV1000
confocal microscope (Central Valley, PA) to obtain single optical
slices from the cell-substratum interface. To visualize f-actin, cells
were stained with a 165 nM solution of rhodamine-phalloidin
(Invitrogen) and imaged using a Nikon Eclipse E400 epifluorescent
microscope equipped with a Q Imaging microimager II camera.
Adhesion Assay
High binding 96-well plates (Corning) were coated with 5 mg/
cm
2 of fibronectin (Sigma) or collagen type I (Cultrex) at 37uC for
1 h. Unbound matrix was removed and wells were blocked with
1 mg/ml BSA in PBS for 1 h. Cell lines were harvested using
EDTA and suspended in DMEM without phenol red supple-
mented with 0.1 mg/ml BSA (DMEM/BSA). Cells were fluores-
cently labeled with 25 mM CMFDA Cell Tracker Green
(Invitrogen) for 20 min, washed with DMEM/BSA, resuspended
at 2.5610
5 cells/ml and incubated for a further 30 min at 37uC.
NeoA was added to wells of the coated 96-well plate at various
concentrations in a volume of 1 ml, followed by the addition of
100 ml of the cell suspension. After 45 min, a baseline reading was
obtained on a Bio-Tek FL600 fluorescent plate reader with an
excitation at 490 nm and emission at 520 nm. Non-adherent cells
were then removed by 3 washes with DMEM/BSA. A second
fluorescence reading was then obtained and adhesion was
calculated as a percentage of cells remaining compared to cells
present in the baseline reading.
Apoptosis and cell viability assays
Cells cultured as attached monolayers were treated with NeoA.
The conditioned medium and one PBS wash were then collected
to recover any detached cells and all remaining adherent cells were
detached with EDTA. All cells were then pooled, collected
through centrifugation, re-suspended in 100 ml binding buffer
(10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) and
incubated with 5 ml FITC Annexin V (BD Biosciences) and 10 ml
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temperature. Staining for PI (relative fluorescence intensity
measured in FL2 channel) and Annexin V (measured in FL1
channel) was assessed by flow cytometry on a FACSCalibur
instrument (BD Biosciences) followed by data analysis using
FlowJo software (Tree Star Inc). DMSO served as a negative
control. A CaspaTag Pan-Caspase fluorescein labeled assay kit
(Chemicon) was used to measure levels of active caspases following
treatment and levels were assessed by flow cytometry in the FL1
channel.
Flow cytometric analysis of cell surface b1 integrin
Cells in suspension were incubated with NeoA for 45 min at
37uC, washed once with PBS, and re-suspended in 200 ml buffer
(PBS, 20 mM glucose, 1% BSA). 2610
5 cells were incubated with
a 1 in 10 dilution of the directly conjugated CD29-FITC pan
antibody (clone K20, Immunotech) for 45 min at room temper-
ature. Levels of bound antibody were measured by flow cytometry
on a FACSCalibur instrument (BD Biosciences) followed by data
analysis (and determination of median peak values) using FlowJo
software (Tree Star Inc).
Immunoblot of cell lysates and conditioned medium
Prior to initiating the experiment, cell cultures were washed 3
times with serum-free medium to remove serum proteins. Cells
were then treated with either DMSO or the indicated concentra-
tion of NeoA in serum-free medium for 45 min at 37uC, after
which the conditioned medium was harvested and concentrated
using 10 kDa cut-off Microcon centrifugal filters (Millipore). Non-
adherent cells were pelleted by centrifugation at 500 g for 6 min at
4uC and kept on ice. The remaining adherent cells and the
centrifuged non-adherent cells were lysed in RIPA buffer
containing protease inhibitors (50 mM Tris pH 7.5, 150 mM
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
20 mg/ml aprotinin, 10 mg/ml leupeptin, 100 mM PMSF, 10 mg/
ml pepstatin A, 2.5 mM EDTA) at 4uC for 30 min with agitation
and then clarified through centrifugation at 10,000 g for 15 min at
4uC. All samples for electrophoresis were quantified with a BCA
protein assay (Pierce) and equalized accordingly prior to
electrophoresis. The following primary antibodies were used:
0.1 mg/ml mouse monoclonal anti-human b1 integrin (extracellu-
lar immunogen, BD Biosciences), 1/500 dilution of rabbit
polyclonal anti-human b1 integrin (cytosolic immunogen
AB1952, Chemicon), 25 ng/ml mouse anti-human paxillin (BD
Biosciences), 1/500 dilution of monoclonal anti-actin (Sigma),
1 mg/ml rabbit polyclonal anti-EGFR (Santa Cruz), and 1 mg/ml
mouse anti-human transferrin receptor (Zymed). To detect
biotinylated protein, an anti-biotin-HRP antibody was used (Cell
Signaling).
Vesicle isolation and characterization
Confluent MDA-MB-231 monolayers in a 10 cm dish were
rinsed with serum-free medium and treated with either DMSO or
13 mM NeoA in 4 ml serum-free, phenol red-free medium. After
45 minutes at 37uC, conditioned medium was collected and all
further steps were conducted at 4uC. Samples were first
centrifuged at 500 g for 10 min to eliminate cells and supernatants
were sequentially centrifuged at 16,500 g for 20 min and
120,000 g for 70 min. Small aliquots of supernatants from each
step were kept aside and pellets for immunoblotting were
suspended in medium. For proteomic analysis, the final vesicle
pellet was solubilized in 50 ml 1% sodium deoxycholate, 50 mM
NH4HCO3. Protein solutions were processed as described [47]
and peptides from the control- and NeoA-treated conditions were
differentially labeled with formaldehyde isotopologues (Cambridge
Isotopes Laboratory) and analyzed on an LTQ-Orbitrap (Ther-
moFisher Scientific, Bremen, Germany) exactly as described [47].
Peptides and proteins were identified from tandem mass spectra
using Mascot (v2.2) to search against the human International
Protein Index database (69,186 sequences) using the following
search parameters: 5 parts-per-million peptide mass accuracy,
0.6 Da fragment mass accuracy, carbamidomethylation of Cys
(fixed), dimethylation (normal and with
2H4) of Lys and N-termini
(variable), ion trap fragmentation characteristics and trypsin
cleavage specificity with up to one missed cleavage. Proteins were
considered identified if at least two unique peptide sequences with
IonsScores over 26 were detected.
Electron microscopy
For TEM, sub-confluent MDA-MB-231 monolayers on 1 mm
pore culture inserts (Falcon 35-3104) were treated for 20 min at
37uC and vesicle pellets were prepared as described below. Cells
on cut-out inserts and vesicle pellets were fixed (1.5% parafor-
maldehyde, 1.5% glutaraldehyde, 0.1 M sodium cacodylate,
pH 7.3) at room temperature for 3 h, placed in buffer (0.1 M
sodium cacodylate, pH 7.3) overnight at room temperature, post-
fixed for 1 h on ice (1:1 mixture of 2% OsO4 in ddH2O and 0.2 M
sodium cacodylate, pH 7.3), washed 3X with ddH2O at room
temperature, stained en bloc for 1 h (1% aqueous uranyl acetate)
and washed again 3X with ddH2O. Finally, samples were
dehydrated through a graded series of ethyl alcohol, passed
through propylene oxide into a 1:1 mixture of propylene oxide and
Polybed embedding resin (Electron Microscopy Sciences, Hatfield,
PA), followed by overnight infiltration and embedding in Polybed.
Thin sections were stained with uranyl acetate and lead citrate,
and photographed on a Philips 300 electron microscope operated
at 60 kV. For SEM, MDA-MB-231 monolayers on serum-coated
glass coverslips were treated 30 min at 37uC, fixed at 37uC (4%
formaldehyde, 2.5% glutaraldehyde, 0.1 M sodium cacodylate,
pH 7.4) in a laboratory microwave (Pelco, Redding, California)
under vacuum for two 100 W cycles of 2 min each without
changing fixative, washed 3X with buffer (0.1 M sodium
cacodylate, pH 7.4) and post-fixed with buffered 1% OsO4.
Samples were then washed 3X with ddH2O, microwave
dehydrated at 28uC through a graded ethanol series (30, 50, 70,
80, 90, 95, 2X 100%) at atmospheric pressure for 40 s, 270 W
each step, one 10 min step at RT, critically point dried (Tousimis
AutoSamDri 815B), mounted to aluminum SEM stubs and sputter
coated (Cressington HR208) with 8 nm gold. Images were
acquired with a Hitachi S4700 FESEM.
Transfection and infection
The EGFR-YFP plasmid was obtained from Z. Wang
(University of Alberta, Edmonton, Canada). Cells were transfected
with the construct using Lipofectamine 2000 (Invitrogen), replated
into chamber slides, and imaged the following day on a spinning
disk confocal microscope. Infection with wild type and dominant
negative dynamin adenoviruses was performed exactly as
described [48]. Viral stocks were a kind gift from I.R. Nabi
(University of BC, Vancouver, Canada).
Live cell imaging
EGFR-YFP-transfected MDA-MB-231 cells were plated on
chamber slides (Ibidi) and maintained at 37uC and 5% CO2 while
being imaged using a spinning disk confocal system consisting of
an inverted Zeiss Axiovert 200 M microscope equipped with a
QuantEM 512SC Photometrics camera. Z-stacks were obtained
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objective (63X/1.4 Oil DIC Planapo).
NeoA isolation, NMR spectroscopy and structure
calculations
Purified NeoA from Neopetrosia sp. [15] was HPLC-purified,
lyophilized, and dissolved in 4:1 C2H3CN/H2O to 8 mM. The
acidic pH of the sample, due to residual trifluoroacetic acid, was
not adjusted. The three dimensional structure of NeoA was
elucidated from natural abundance 2D
1H,
1H-DQF-COSY,
1H,
1H-TOCSY,
15N,
1H-HSQC,
13C,
1H-HSQC,
1H,
1H-NOESY
(tmix=300 ms), and
13C,
1H-HSQC-NOESY (tmix=300 ms) spec-
tra, recorded at 25uC on Varian Inova or Bruker Avance
600 MHz NMR spectrometers equipped with cryoprobes. Spectra
were processed using nmrPipe [49] and analyzed using Sparky
(T.D. Goddard, D.G. Kneller, Sparky 3, University of California,
http://www.cgl.ucsf.edu/home/sparky/). A weak set of additional
amide
1H
N-
15N resonances, attributed to disulfide bond isomer-
ization, was observed for several residues (Phe2, Cys3, Phe5, Gly6,
Cys7, Cys12, Gly13, Asn15, Arg19, Phe23, Cys26, Asp27, Cys28)
in the
15N,
1H-HSQC spectrum of NeoA; these were excluded
during the structural analysis. Also, since the absolute stereo-
chemistry of the methionine sulfoxide is not known, an R-
configuration was arbitrarily set at the sulfur stereocenter. An
initial ensemble averaged structure was calculated from a linear
template with ARIA [50] using manually-assigned NOE-derived
distance restraints in combination with distance constraints
(Cbi2Cbj,C bi2Scj,S ci2Cbj,S ci2Scj) for the previously
identified Cys32Cys26, Cys72Cys12, and Cys182Cys28 pairs
[15]. Once approximately positioned, covalent disulfide bonds
were introduced between these Cys residues, and a set of 200
structures calculated using CNS [51], from which the 24 lowest
energy structures were selected to yield the final NeoA structural
ensemble. A summary of the restraints and structural statistics for
this ensemble is provided in Table S1 and the coordinated
structures have been deposited in the Research Collaboratory for
Structural Bioinformatics Protein Databank (http://www.rcsb.
org/pdb/) under accession code 2JUY. Promotif [52] was used to
identify secondary structure elements in the final ensemble.
Supporting Information
Table S1 NMR and refinement statistics for NeoA.
Found at: doi:10.1371/journal.pone.0010836.s001 (0.04 MB
DOC)
Figure S1 NeoA prevents HT-1080 cell elongation and invasion
into Matrigel. (A) HT-1080 cells were treated with NeoA (or 5 mM
dihydromotuporamine C as a positive control, +ve) in constant
amounts of DMSO. Cells that failed to invade were recovered and
quantified through an MTT assay. Shown are averages of
triplicates 6 SD. **P,0.005, ***P,0.0005 compared to 0 mM
as determined by two-tailed Student’s t-test. (B) HT-1080 cells
were plated on the reconstituted basement membrane substratum
Matrigel in the presence of DMSO vehicle alone or 6.5 mM NeoA
and morphology was assessed by live phase contrast microscopy
after 2.5 h. Scale bar, 50 mm. (C) NeoA treatment results in loss of
polarity and decreased actin ruffling. f-actin was visualized with
fluorescently labeled phalloidin after HT-1080 cells had been
treated with either DMSO or 3.2 mM NeoA for 90 min. Scale bar,
10 mm.
Found at: doi:10.1371/journal.pone.0010836.s002 (0.81 MB TIF)
Figure S2 NeoA inhibits cellular adhesion and causes the
disassembly of focal adhesions in HT-1080 cells. (A) Cells treated
for 1 h with DMSO (control) or 6.5 mM NeoA were fluorescently
stained for the focal adhesion proteins paxillin, vinculin, and
phosphorylated focal adhesion kinase (pFAK). Note that all
proteins were no longer localized at discrete attachment sites (i.e.
focal adhesions) in NeoA-treated cells. Scale bar, 10 mm. (B)
Adhesion to fibronectin (FN) and collagen type I (Col I) is
significantly decreased in the presence of NeoA. Shown are
averages of triplicates 6 SD. ** P,0.05, *** P,0.005 compared
to 0 mM as determined by two-tailed Student’s t-test. (C) Cells pre-
attached on fibronectin begin to lose adherence between 10 to
25 min after the start of treatment with 6.5 mM NeoA. Scale bar,
50 mm.
Found at: doi:10.1371/journal.pone.0010836.s003 (1.84 MB TIF)
Figure S3 NeoA is slightly toxic to cells after 24 h. Cell death
and apoptosis of MDA-MB-231 cells treated with the indicated
concentrations of NeoA for 24 h were determined by assessing
propidium iodide uptake (y axis) and Annexin V staining (x axis)
by flow cytometry. Cells undergoing apoptosis stain positively for
Annexin V-FITC alone and would appear in the lower right
quadrant of the plots. Dead cells are PI-positive and appear in the
upper quadrants, either without having undergone apoptosis
(upper left quadrant) or after having undergone apoptosis (upper
right quadrant).
Found at: doi:10.1371/journal.pone.0010836.s004 (0.14 MB TIF)
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